Interim Director, University of Ottawa Brain & Mind Research Institute
Bhargava Research Chair in Neurodegeneration , The Ottawa Hospital
Director, Neuroscience Research Program , Ottawa Hospital Research Institute
Neurologist, The Ottawa Hospital
Dr. Michael Schlossmacher is a clinician scientist focused on improving the lives of individuals with neurodegenerative diseases. In July 1987, following completion of medical school in Vienna, Austria, he began graduate studies in human biology. A Fulbright Commission scholarship enabled him to visit Harvard University. He subsequently pursed post-doctoral work on the molecular pathology of Alzheimer disease in the laboratory of Dr. Dennis J. Selkoe (1988-1992). This led to his co-discovery of the physiological release of amyloid beta protein by cultured cells into biological fluids (Nature 1992), an essential building block for the ‘amyloid hypothesis’ of Alzheimer disease.
Following residency training in general medicine in Vienna (1995), Dr. Schlossmacher completed adult neurology training in the Harvard Longwood Neurology Program (1999) and a clinical fellowship in movement disorders at Brigham & Women’s Hospital and Massachusetts General Hospital (1999-2001). Since 2000, he has focused his research activities on Parkinson disease and related dementias. In 2003, he became an independent investigator at the Center for Neurologic Diseases at Brigham & Women’s Hospital and was appointed Assistant Professor in Neurology at Harvard Medical School in 2004.
Recruited by the Ottawa Hospital Research Institute and University of Ottawa with support from the Canada Research Chair Program (tier 2), Dr. Schlossmacher opened a new laboratory as a member of the Parkinson’s Research Consortium Ottawa in early 2007. From 2009 to 2018, Dr. Schlossmacher also served as the Founding Director of the MD/PhD Program at the Faculty of Medicine at uOttawa. In October 2012, he was named the Bhargava Research Chair in Neurodegeneration at The Ottawa Hospital. The appointment was made possible through the generous support from Mrs. Uttra and Mr. Sam Bhargava and their family. In 2013, he was promoted to Full Professor at the Faculty of Medicine, and in 2015, he was appointed Director of the Neuroscience Program (to succeed Dr. Antoine Hakim). In September 2018, he was asked to take on the role as Interim Director of the uOttawa Brain and Mind Research Institute until a successor for Dr. David Park has been named.
Since 2000, Dr. Schlossmacher has pursued work as a physician-scientist focusing on Parkinson disease (PD), Lewy body dementia (DLB) and multiple system atrophy (MSA). Since opening a new laboratory at the OHRI in 2007, his team has focused on: (i) better modeling of the pathogenesis of these diseases; (ii) understanding the functions of four disease-linked genes (SNCA; GBA; LRRK2; Parkin); (iii) creating new research tools including animal models, assays and antibodies; and (iv) exploring biological markers of parkinsonism to assist in diagnosis and prediction of course.